Alzinova to participate at CTAD 2025 with two presentations on ALZ-101
Idag, 14:39
Alzinova AB (publ) (Nasdaq First North: ALZ), a Swedish biotechnology company developing disease-modifying treatments for Alzheimer’s disease, today announced that two abstracts on the vaccine candidate ALZ-101 have been accepted for presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025, to be held December 1–4 in San Diego, USA.
”Being invited to present at CTAD is an important milestone for us at Alzinova. The conference brings together world-leading expertise and gives us an opportunity to position our vaccine candidate ALZ-101 and build valuable collaborations ahead of the next development phase,” says Tord Labuda, CEO of Alzinova AB.
The two presentations focus on clinical data from the Phase 1b study of ALZ-101, as well as on new biomarker findings showing the presence of naturally occurring antibodies against neurotoxic Aβ oligomers. Together, these data provide further support for the disease-modifying potential of ALZ-101 and validate the underlying AβCC technology.
The manuscript for the scientific article describing the complete results from the Phase 1b study is being finalized and will soon be submitted for publication in a leading peer-reviewed journal, ensuring broad dissemination and high scientific credibility. To ensure proper publication procedures, all data will be made public only in conjunction with the publication of the scientific article.
Presentations
P065 – Results from a Phase 1b trial on anti-Aβ oligomer vaccine ALZ-101 in early Alzheimer’s disease
Presenter: Anders Sandberg, PhD, Chief Scientific Officer, Alzinova.
Key results
- ALZ-101 was well tolerated and immunogenic at all doses, with a 90% IgG responder rate.
- Asymptomatic ARIA-H was observed in 9 of 32 patients during the study, but only in participants with pre-existing lesions, likely reflecting a predisposition rather than a treatment-induced effect.
- Only one asymptomatic ARIA-E was observed in a single individual after four doses of ALZ-101; this event was assessed as not drug-induced.
- Stabilization of cognition/function and CSF biomarker levels (NfL, pTau-181, T-tau) over two years in vaccinated individuals suggests a markedly slower disease progression compared with historical controls.
P203 – Naturally Occurring IgG Targeting Neurotoxic Aβ42 Oligomers in Healthy Elderly
Presenter: Stefan Pierrou, Vice President R&D Projects, Alzinova and Anders Sandberg.
Key results
- Naturally occurring IgG antibodies against the Aβ42CC oligomer were identified in both healthy individuals and Alzheimer’s patients.
- Healthy elderly individuals (mean age 66.4 ± 3.6 years) had on average 1.6 times higher IgG levels than healthy younger individuals (mean age 26.7 ± 1.5 years) and 1.8 times higher levels than participants in ALZ-C-001 (mean age 68.6 ± 6.4 years).
- Vaccinated individuals in study ALZ-C-001 showed vaccine-induced IgG levels comparable to naturally occurring levels in healthy elderly.
”CTAD is an important platform for clinical progress in the Alzheimer’s field, and our participation marks a key milestone for Alzinova. The data we present suggest that ALZ-101 may uniquely affect AD pathology through its Aβ-oligomer-specific antibody response, although larger studies are needed to confirm its potential” says Anders Sandberg, Chief Scientific Officer of Alzinova.
About CTAD
The Clinical Trials on Alzheimer’s Disease (CTAD) conference is one of the world’s leading scientific meetings on drug development for Alzheimer’s disease. CTAD brings together researchers, pharmaceutical companies, and regulatory experts from around the globe to discuss the latest advances in clinical trials and new therapeutic approaches.
Learn more about CTAD on their website: https://www.ctad-alzheimer.com/
For further information, please contact:
Tord Labuda, CEO
E-mail: info@alzinova.com
About Alzinova AB
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com
Attachments
Alzinova to participate at CTAD 2025 with two presentations on ALZ-101
Ämnen i artikeln
Alzinova to participate at CTAD 2025 with two presentations on ALZ-101
Idag, 14:39
Alzinova AB (publ) (Nasdaq First North: ALZ), a Swedish biotechnology company developing disease-modifying treatments for Alzheimer’s disease, today announced that two abstracts on the vaccine candidate ALZ-101 have been accepted for presentation at the Clinical Trials on Alzheimer’s Disease (CTAD) 2025, to be held December 1–4 in San Diego, USA.
”Being invited to present at CTAD is an important milestone for us at Alzinova. The conference brings together world-leading expertise and gives us an opportunity to position our vaccine candidate ALZ-101 and build valuable collaborations ahead of the next development phase,” says Tord Labuda, CEO of Alzinova AB.
The two presentations focus on clinical data from the Phase 1b study of ALZ-101, as well as on new biomarker findings showing the presence of naturally occurring antibodies against neurotoxic Aβ oligomers. Together, these data provide further support for the disease-modifying potential of ALZ-101 and validate the underlying AβCC technology.
The manuscript for the scientific article describing the complete results from the Phase 1b study is being finalized and will soon be submitted for publication in a leading peer-reviewed journal, ensuring broad dissemination and high scientific credibility. To ensure proper publication procedures, all data will be made public only in conjunction with the publication of the scientific article.
Presentations
P065 – Results from a Phase 1b trial on anti-Aβ oligomer vaccine ALZ-101 in early Alzheimer’s disease
Presenter: Anders Sandberg, PhD, Chief Scientific Officer, Alzinova.
Key results
- ALZ-101 was well tolerated and immunogenic at all doses, with a 90% IgG responder rate.
- Asymptomatic ARIA-H was observed in 9 of 32 patients during the study, but only in participants with pre-existing lesions, likely reflecting a predisposition rather than a treatment-induced effect.
- Only one asymptomatic ARIA-E was observed in a single individual after four doses of ALZ-101; this event was assessed as not drug-induced.
- Stabilization of cognition/function and CSF biomarker levels (NfL, pTau-181, T-tau) over two years in vaccinated individuals suggests a markedly slower disease progression compared with historical controls.
P203 – Naturally Occurring IgG Targeting Neurotoxic Aβ42 Oligomers in Healthy Elderly
Presenter: Stefan Pierrou, Vice President R&D Projects, Alzinova and Anders Sandberg.
Key results
- Naturally occurring IgG antibodies against the Aβ42CC oligomer were identified in both healthy individuals and Alzheimer’s patients.
- Healthy elderly individuals (mean age 66.4 ± 3.6 years) had on average 1.6 times higher IgG levels than healthy younger individuals (mean age 26.7 ± 1.5 years) and 1.8 times higher levels than participants in ALZ-C-001 (mean age 68.6 ± 6.4 years).
- Vaccinated individuals in study ALZ-C-001 showed vaccine-induced IgG levels comparable to naturally occurring levels in healthy elderly.
”CTAD is an important platform for clinical progress in the Alzheimer’s field, and our participation marks a key milestone for Alzinova. The data we present suggest that ALZ-101 may uniquely affect AD pathology through its Aβ-oligomer-specific antibody response, although larger studies are needed to confirm its potential” says Anders Sandberg, Chief Scientific Officer of Alzinova.
About CTAD
The Clinical Trials on Alzheimer’s Disease (CTAD) conference is one of the world’s leading scientific meetings on drug development for Alzheimer’s disease. CTAD brings together researchers, pharmaceutical companies, and regulatory experts from around the globe to discuss the latest advances in clinical trials and new therapeutic approaches.
Learn more about CTAD on their website: https://www.ctad-alzheimer.com/
For further information, please contact:
Tord Labuda, CEO
E-mail: info@alzinova.com
About Alzinova AB
Alzinova AB is a Swedish biopharmaceutical company in clinical development specializing in the treatment of Alzheimer's disease, where the starting point is to attack toxic amyloid-beta oligomers. The lead candidate ALZ-101 is a therapeutic vaccine against Alzheimer's disease. Alzinova's patented AβCC peptide technology makes it possible to develop disease-modifying treatments that target the toxic amyloid-beta oligomers that are central to the onset and development of the disease with great accuracy. From a global perspective, Alzheimer's disease is one of the most common and devastating neurological diseases, with around 40 million affected today. Based on the same technology, the company is also developing the antibody ALZ-201, which is currently in preclinical development, and the goal is to further expand the pipeline. The company's Certified Adviser on Nasdaq First North Growth Market is Mangold Fondkommission AB. For more information about Alzinova, please visit: www.alzinova.com
Attachments
Alzinova to participate at CTAD 2025 with two presentations on ALZ-101
Ämnen i artikeln
Analyser
Intellego rasar kraftigt efter rapport
Analyser
Intellego rasar kraftigt efter rapport
Mest läst
Marknadsöversikt
1 DAG %
Senast
1 mån
